Exponent, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 29, 2023 (52 weeks), compared with fiscal 2022 ended December 30, 2022. The request metadata says “2022 Q4,” but the supplied filing is the 2023 annual report, not a 2022 quarterly filing.
Business context and results
Exponent is a science and engineering consulting firm serving clients across industries through two reportable segments: Engineering and Other Scientific, and Environmental and Health. Its project-based engagements are generally billed on a time-and-materials or fixed-price basis; clients may terminate or delay work, and backlog is not a reliable indicator of future revenue.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $536.8 million, up 4.6% | $513.3 million |
| Revenue before reimbursements | $497.2 million, up approximately 7% | $463.8 million |
| Operating income and margin | $111.3 million; 20.7% | $140.8 million; 27.4% |
| Net income and margin | $100.3 million; 18.7% | $102.3 million; 19.9% |
| Diluted EPS | $1.94 | $1.96 |
| Operating cash flow | $127.4 million | $93.8 million |
| Cash and cash equivalents, year-end | $187.2 million | $161.5 million |
Segment performance and material changes
- Engineering and Other Scientific: Revenue was $446.9 million, up 4.5%; segment operating income was $153.9 million, up 0.8%. Growth was driven principally by transportation and energy demand.
- Environmental and Health: Revenue was $89.9 million, up 5.1%; segment operating income was $28.4 million, up 4.0%. Higher billing rates more than offset lower billable hours, with safety-related chemical health and environmental work supporting growth.
- Total billable hours rose 2% to 1.495 million, while utilization declined to 69% from 74%. Technical full-time-equivalent employees increased 10% to 1,047.
- Operating income fell 21% despite higher revenue. Compensation and related expenses rose 21.1% to $319.9 million, including higher wages and benefits, workforce growth, and a $28.5 million increase in deferred-compensation expense. The corresponding investment gains were recorded in other income.
- Other income was $24.6 million, compared with an $8.6 million loss in 2022, reflecting deferred-compensation investment performance and higher interest income. The effective tax rate increased to 26.2% from 22.6%, partly because the excess tax benefit from stock awards declined.
Cash, liquidity, debt, and capital allocation
Operating cash flow was $127.4 million; investing cash use was $16.4 million, primarily capital expenditures; and financing cash use was $86.0 million. Capital expenditures were $18.7 million in the segment disclosure, including investment in corporate infrastructure and office/lab improvements. Management said cash and cash equivalents should be sufficient for working capital, capital expenditures, commitments, repurchases, dividends, and other needs for at least the next 12 months.
The filing does not report conventional borrowings or a debt balance in the supplied financial statements. It does report $28.3 million of operating lease liabilities and $116.6 million of vested deferred-compensation obligations at year-end. The company paid $54.0 million in dividends and repurchased $24.2 million of stock during 2023. The quarterly dividend was $0.26 per share in 2023; after year-end, the board declared $0.28 per share and authorized an additional $61.6 million for repurchases.
Outlook, risks, and unusual items
- No specific revenue, earnings, or margin guidance is provided. Fiscal 2024 is a 53-week year ending January 3, 2025. Management expects other operating expenses to grow as it selectively hires and invests in corporate infrastructure.
- Management highlighted continued demand for multidisciplinary services and plans to pursue emerging growth areas, develop technical talent, manage expenses, generate operating cash, and return capital through dividends and repurchases.
- Key risks include variable and reactive project demand, limited backlog, client cancellations or delays, competition and pricing pressure, attracting and retaining specialized employees, and dependence on professional reputation. Client exposure is diversified; no single client represented more than 10% of 2023 revenue.
- Other disclosed risks include professional liability and litigation, regulatory or tort-reform changes that could reduce demand, cybersecurity and data privacy, government-contract compliance, international and foreign-exchange exposure, inflation and other cost increases, and economic or geopolitical disruption.
- The company reported no material legal proceedings and no goodwill or long-lived-asset impairment in 2023. The auditor identified collectibility of accounts receivable as a critical audit matter; year-end net receivables were $167.4 million and the allowance for contract losses and doubtful accounts was $5.3 million.
- Deferred-compensation investment gains and losses materially affected reported other income and compensation expense, with offsetting entries; investors should distinguish this volatility from underlying consulting operations.
Important facts for investors to verify
- Confirm the filing period: the supplied document covers fiscal 2023, despite the request metadata indicating 2022 Q4.
- Review the drivers and sustainability of the lower utilization rate and the sharp increase in compensation costs relative to revenue growth.
- Assess receivables collection, unbilled work, and the allowance, given the auditor’s critical audit matter and the material receivables balance.
- Separate deferred-compensation investment gains and losses from operating performance when evaluating earnings trends.
- Monitor cash deployment, lease obligations, dividend and repurchase authorizations, and the absence of a stated numerical outlook.